Results 31 to 40 of about 78,032 (168)

Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura.

New England Journal of Medicine, 2019
Managing Acquired TTP without Plasma Exchange A case of acquired thrombotic thrombocytopenic purpura is reported in a Jehovah’s Witness who had neurologic manifestations but would not accept plasma...
Deepak P. Chander, M. Loch, S. Cataland, J. George   +3 more
semanticscholar   +1 more source

Tuberculosis associated thrombocytopenic purpura: effectiveness of antituberculous therapy

Hematology Reports, 2009
Association of immune thrombocytopenic purpura and tuberculosis is a rare condition. In 5 patients presenting with this association, anti-tuberculous therapy was effective on both tuberculosis and thrombocytopenia suggesting a causal relationship between
Raphael Borie, Claire Fieschi, Eric Oksenhendler, Lionel Galicier   +3 more
doaj   +1 more source

Progress in Aptamer Research and Future Applications

ChemistryOpen, EarlyView.
This paper mainly describes the screening method of aptamer, the screening difficulties and improvement methods of small molecule aptamer, and the application and treatment of aptamer. It explores the latest progress and application of aptamers, and summarises them, thus indicating some problems that still exist in this field.
Song Liu, Xiaolu Li, Huyang Gao, Jing Chen, Hongfeng Jiang   +4 more
wiley   +1 more source

Purpura with regular shape in an adolescent: Beware of dermatitis artefacta

Frontiers in Pediatrics, 2022
BackgroundPurpura is common in pediatric patients, mostly diagnosed as IgA-related vasculitis (Henoch–Schönlein purpura), idiopathic thrombocytopenic purpura (ITP), and thrombotic thrombocytopenic purpura (TTP). However, in some cases, for example, cases
Yuhao Chen, Yuhao Chen, Lin Li, Jing Lu, Jing Lu   +4 more
doaj   +1 more source

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

Journal of Thrombosis and Haemostasis, 2019
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti‐von Willebrand Factor Nanobody®, is effective for treating aTTP episodes and is well tolerated.
P. Knoebl, S. Cataland, F. Peyvandi, P. Coppo, M. Scully, J. K. Kremer Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, Jessica Minkue Mi Edou, H. de Winter, F. Callewaert   +11 more
semanticscholar   +1 more source

Target‐Mediated Drug Disposition (TMDD) Revisited: High Versus Low‐Affinity Approximations of the TMDD Model

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Target‐mediated drug disposition (TMDD) is often associated with high‐affinity binding to a target resulting in nonlinear pharmacokinetics. For large molecules, such as monoclonal antibodies, this can lead to increased clearance at sub‐saturating concentrations.
Ronny Straube
wiley   +1 more source

Using plasma exchange to successfully manage thyrotoxicosis in a patient with possible antithyroid drug-related thrombotic thrombocytopenic purpura

Endocrine Regulations, 2017
Objective. Thrombotic thrombocytopenic purpura (TTP) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenic purpura, neurologic abnormalities, fever, and renal insufficiency.
Tazegul G, Ogut TS, Bozoglan H, Dogan O, Yilmaz N, Ulas T, Salim O, Sari R, Altunbas HA, Balci MK   +9 more
doaj   +1 more source

CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura

Haematologica, 2011
Immune thrombocytopenic purpura is an acquired autoimmune disorder that is the most common cause of thrombocytopenia in children. The endocannabinoid system is involved in immune regulation.
Francesca Rossi, Silvia Mancusi, Giulia Bellini, Domenico Roberti, Francesca Punzo, Simona Vetrella, Sofia Maria Rosaria Matarese, Bruno Nobili, Sabatino Maione, Silverio Perrotta   +9 more
doaj   +1 more source

Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine

Research and Practice in Thrombosis and Haemostasis, 2018
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy characterized by severe congenital or immune‐mediated deficiency in ADAMTS13, the enzyme that cleaves von Willebrand factor multimers.
P. Coppo, A. Cuker, J. George
semanticscholar   +1 more source

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management of VWD all utilised GRADE methodology.
Mark W. Skinner, Manuela Albisetti, Jesús Ardila, Jan Astermark, Jan Blatny, Manuel Carcao, Pratima Chowdary, Nathan T. Connell, Miguel Crato, Yesim Dargaud, Roseline d'Oiron, Amy L. Dunn, Miguel A. Escobar, Carmen Escuriola‐Ettingshausen, Emna Gouider, Annie Harroche, Cedric Hermans, Victor Jimenez‐Yuste, Radoslaw Kaczmarek, Gili Kenet, Liane Khoo, Robert Klamroth, Florian Langer, David Lillicrap, Johnny Mahlangu, Christoph Male, Tadashi Matsushita, Sandrine Meunier, Wolfgang Miesbach, Beatrice Nolan, Johannes Oldenburg, Brian O'Mahony, Margareth Ozelo, Glenn F. Pierce, Gloria Ramos, Michael Recht, Olivia Romero‐Lux, Dawn Rotellini, Rita C. Santoro, Tammuella C. Singleton, Alok Srivastava, Sophie Susen, Kate Talks, Huyen Tran, Leonard A. Valentino, Jerzy Windyga, Renchi Yang, Maria Elisa Mancuso, also on behalf of AICE, AHAD‐AP, AHCDC, ATHN, CLAHT, EHC, French CRH & MHEMO, HTCCNC, NBDF, PEDNET, UKHCDO, WFH   +59 more
wiley   +1 more source